DNA The DNA Core located in the Eckstein Medical Research Building adjacent to the Holden Cancer Research Laboratories supports research performed by investigators in all HCCC programs. It provides a broad spectrum of services and resources designed to make the state-of-the-art techniques used in DNA sequence and transcript analysis readily available to the University of lowa research community. These services and resources include: 1) DNA sequencing, 2) custom oligonucleotides, 3) DNA microarrays using both the Affymetrix GeneChip system and the custom spotted array using the microscope slide format, 4) real-time PCR, 5) molecular biology computing, and 6) genome sequencing using next generation sequencing technologies. It is the aim of the DNA Core to provide high quality services to HCCC members with a rapid turnaround and support these services with well-trained personnel. The core also continues to evaluate andupdate their services so they remain cutting-edge and provides new services, as needed, to continue to meet the needs of HCCC investigators. In 2009, the DNA Core provided services to 82 HCCC members with peer reviewed funding.

Public Health Relevance

The DNA Core is highly cancer relevant. The services it provides, including state-of-the-art DNA sequencing, production of custom oligonucleotides, and microarray analysis, are necessary tools for the conduct of modern molecular cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-13
Application #
8466216
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
13
Fiscal Year
2013
Total Cost
$77,756
Indirect Cost
$31,207
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Reiner, Anne S; Sisti, Julia; John, Esther M et al. (2018) Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol 36:1513-1520
Liu, Q; Kulak, M V; Borcherding, N et al. (2018) A novel HER2 gene body enhancer contributes to HER2 expression. Oncogene 37:687-694
Arthur, Rhonda; Wassertheil-Smoller, Sylvia; Manson, JoAnn E et al. (2018) The Combined Association of Modifiable Risk Factors with Breast Cancer Risk in the Women's Health Initiative. Cancer Prev Res (Phila) 11:317-326
Press, Robert H; Shu, Hui-Kuo G; Shim, Hyunsuk et al. (2018) The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. Int J Radiat Oncol Biol Phys 102:1219-1235
Viala, Marie; Chiba, Akiko; Thezenas, Simon et al. (2018) Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study. BMC Cancer 18:770
Madsen, Mark T; Menda, Yusuf; O'Dorisio, Thomas M et al. (2018) Technical Note: Single time point dose estimate for exponential clearance. Med Phys 45:2318-2324
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Sabree, Shakoora; Berg, Daniel; Sato, Mariko (2018) Treatment of a pediatric patient with MET-amplified signet ring cell adenocarcinoma of the stomach with crizotinib. Pediatr Blood Cancer 65:e26984
Bharti, Sanjay Kumar; Sommers, Joshua A; Awate, Sanket et al. (2018) A minimal threshold of FANCJ helicase activity is required for its response to replication stress or double-strand break repair. Nucleic Acids Res 46:6238-6256
Zeliadt, Steven B; Hoffman, Richard M; Birkby, Genevieve et al. (2018) Challenges Implementing Lung Cancer Screening in Federally Qualified Health Centers. Am J Prev Med 54:568-575

Showing the most recent 10 out of 1080 publications